BETA
Your AI-Trained Oncology Knowledge Connection!
The panel continues their discussion on adverse effect management with a focus on GPRC5D-targeting bispecific antibodies in multiple myeloma.
Stay up to date on recent advances in the multidisciplinary approach to cancer.
FDA Removes REMS, Lessens Requirements of Liso-cel/Ide-cel in Blood Cancers
The FDA had reduced driving and geographic restrictions to 2 weeks for patients with lymphomas and multiple myeloma receiving liso-cel and ide-cel.
Mitigating AEs and Protecting QOL Following Talquetamab in Multiple Myeloma
Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.
Etentamig Displays Durable Responses, Tolerability in R/R Multiple Myeloma
Efficacy with etentamig was comparable across prespecified subgroups with relapsed/refractory multiple myeloma, suggesting broad therapeutic benefit.
Exploring the Potential Role of JAK Inhibitors in Multiple Myeloma
James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.
Data Show Enduring Responses With Talquetamab Combo in R/R Multiple Myeloma
Findings from the phase 1b TRIMM-3 trial support the potential activity of PD-1 inhibition in patients with relapsed/refractory multiple myeloma.
Elranatamab Triplet Induces Early and Deep Responses in Newly Diagnosed MM
The MagnetisMM-6 trial results showed that elranatamab plus daratumumab and lenalidomide yielded an ORR of 97.3% in transplant-ineligible multiple myeloma.